HY-022619

1. Primary objective: To evaluate the safety and tolerability of a single injection of different doses of HY-022619 for injection in healthy subjects. 2. Secondary objectives 1) To evaluate the pharmacokinetic (PK) characteristics of a single injection of different doses of HY-022619 for injection in healthy subjects; 2) To evaluate the pharmacodynamic (PD) characteristics of a single injection of different doses of HY-022619 for injection in healthy subjects; 3) To evaluate the differences in pharmacokinetic/pharmacodynamic characteristics after a single intravenous injection of HY-022619 and a single oral administration of ticagrelor tablets in healthy subjects. Exploratory objective: To evaluate the PK/PD correlation after a single administration of different doses of HY-022619 for injection in healthy subjects.